158.88
price up icon0.64%   1.01
after-market 시간 외 거래: 158.88
loading
전일 마감가:
$157.87
열려 있는:
$157.41
하루 거래량:
452.34K
Relative Volume:
0.69
시가총액:
$8.13B
수익:
$638.50M
순이익/손실:
$-183.17M
주가수익비율:
-43.01
EPS:
-3.6943
순현금흐름:
$-93.89M
1주 성능:
+3.09%
1개월 성능:
-14.66%
6개월 성능:
+37.02%
1년 성능:
+26.20%
1일 변동 폭
Value
$156.40
$159.53
1주일 범위
Value
$153.66
$161.36
52주 변동 폭
Value
$86.99
$191.50

Axsome Therapeutics Inc Stock (AXSM) Company Profile

Name
명칭
Axsome Therapeutics Inc
Name
전화
(212) 332-3241
Name
주소
ONE WORLD TRADE CENTER, 29TH FLOOR, NEW YORK
Name
직원
925
Name
트위터
Name
다음 수익 날짜
2026-02-23
Name
최신 SEC 제출 서류
Name
AXSM's Discussions on Twitter

Compare AXSM vs VRTX, REGN, ARGX, ALNY, ONC

주식 가격 시가총액 매출 순이익 현금흐름 주당 순 이익
Biotechnology icon
AXSM
Axsome Therapeutics Inc
158.88 8.08B 638.50M -183.17M -93.89M -3.6943
Biotechnology icon
VRTX
Vertex Pharmaceuticals Inc
458.05 114.72B 12.07B 3.95B 3.19B 15.33
Biotechnology icon
REGN
Regeneron Pharmaceuticals Inc
737.45 78.67B 14.34B 4.50B 3.77B 41.56
Biotechnology icon
ARGX
Argen X Se Adr
684.50 42.38B 4.16B 1.29B 734.26M 19.59
Biotechnology icon
ALNY
Alnylam Pharmaceuticals Inc
311.10 41.75B 3.71B 313.75M 465.38M 2.2571
Biotechnology icon
ONC
Beone Medicines Ltd Adr
282.72 31.33B 5.36B 287.73M 924.18M 2.5229

Axsome Therapeutics Inc Stock (AXSM) Upgrades & Downgrades

날짜 액션 분석자 등급 변경
2026-02-24 개시 Wolfe Research Outperform
2026-01-08 다운그레이드 Morgan Stanley Overweight → Equal-Weight
2025-10-01 개시 B. Riley Securities Buy
2025-09-03 재개 Wells Fargo Overweight
2025-07-03 재개 Morgan Stanley Overweight
2025-06-03 개시 Oppenheimer Outperform
2025-04-07 개시 Jefferies Buy
2025-02-11 개시 Deutsche Bank Buy
2024-12-31 재확인 Mizuho Outperform
2024-09-03 개시 Wells Fargo Overweight
2024-08-06 업그레이드 BofA Securities Neutral → Buy
2024-07-22 개시 Needham Buy
2024-04-29 업그레이드 Morgan Stanley Equal-Weight → Overweight
2024-03-19 개시 Robert W. Baird Outperform
2024-02-06 개시 UBS Buy
2024-01-25 개시 RBC Capital Mkts Outperform
2023-12-13 개시 Citigroup Buy
2023-08-08 업그레이드 BofA Securities Underperform → Neutral
2023-01-05 개시 Piper Sandler Neutral
2022-11-01 개시 Loop Capital Buy
2022-09-07 재개 Mizuho Buy
2021-08-10 다운그레이드 Morgan Stanley Overweight → Equal-Weight
2021-06-10 개시 Berenberg Buy
2021-01-08 개시 Jefferies Buy
2020-12-16 개시 Mizuho Buy
2020-09-29 개시 BofA Securities Underperform
2020-09-10 개시 Morgan Stanley Overweight
2020-04-28 재확인 H.C. Wainwright Buy
2020-04-14 개시 Cowen Outperform
2019-12-30 재확인 H.C. Wainwright Buy
2019-12-17 재확인 H.C. Wainwright Buy
2019-12-16 재확인 Guggenheim Buy
2019-10-16 개시 Guggenheim Buy
2019-09-18 개시 William Blair Outperform
2019-05-28 개시 SunTrust Buy
2019-05-23 재확인 H.C. Wainwright Buy
2019-04-08 개시 SVB Leerink Outperform
2019-03-15 재확인 H.C. Wainwright Buy
2016-10-03 재개 Brean Capital Buy
2015-12-15 개시 Cantor Fitzgerald Buy
2015-12-14 개시 Ladenburg Thalmann Buy
모두보기

Axsome Therapeutics Inc 주식(AXSM)의 최신 뉴스

pulisher
Mar 18, 2026

Axsome Therapeutics’ Q4 numbers beat Wall Street expectations: Analyst sees over 23% upside for stock - MSN

Mar 18, 2026
pulisher
Mar 18, 2026

Superstring Capital's New Axsome Therapeutics Position: A $6.84M Biopharma InvestmentNews and Statistics - IndexBox

Mar 18, 2026
pulisher
Mar 18, 2026

This New $7 Million Bet Targets a CNS Drug Maker With Phase 3 Trial Underway and 27% Stock Gain - AOL.com

Mar 18, 2026
pulisher
Mar 18, 2026

Wolfe Research initiates coverage of Axsome Therapeutics (AXSM) with outperform recommendation - MSN

Mar 18, 2026
pulisher
Mar 18, 2026

Axsome shares slip despite fourth-quarter earnings beat and strong revenue growth - MSN

Mar 18, 2026
pulisher
Mar 17, 2026

(AXSM) Risk Channels and Responsive Allocation - Stock Traders Daily

Mar 17, 2026
pulisher
Mar 17, 2026

Axsome Therapeutics CEO Completes Planned $6 Million Options Sale Ahead of Pivotal FDA Decision - AOL.com

Mar 17, 2026
pulisher
Mar 16, 2026

Axsome Therapeutics, Inc. (NASDAQ:AXSM) Receives Average Recommendation of "Moderate Buy" from Analysts - MarketBeat

Mar 16, 2026
pulisher
Mar 15, 2026

Axsome Therapeutics, Inc. $AXSM Shares Purchased by Eventide Asset Management LLC - MarketBeat

Mar 15, 2026
pulisher
Mar 14, 2026

A Look At Axsome Therapeutics (AXSM) Valuation As Legal Probe And FDA Decision Draw Investor Focus - simplywall.st

Mar 14, 2026
pulisher
Mar 13, 2026

Profit Review: How much upside does Axsome Therapeutics Inc have2026 Outlook & Precise Swing Trade Entry Alerts - baoquankhu1.vn

Mar 13, 2026
pulisher
Mar 13, 2026

AXSM's 2025 Revenue Growth Primarily Fueled by Auvelity: What Does the Future Hold? - Bitget

Mar 13, 2026
pulisher
Mar 13, 2026

AXSM's 2025 Revenue Surge Largely Driven by Auvelity: What's Ahead? - TradingView

Mar 13, 2026
pulisher
Mar 13, 2026

RBC Capital reiterates Axsome Therapeutics stock rating at Outperform By Investing.com - Investing.com Canada

Mar 13, 2026
pulisher
Mar 12, 2026

Axsome Therapeutics Highlights Auvelity’s $500M+ Run, FDA Catalyst and Late-Stage Pipeline at Conference - MarketBeat

Mar 12, 2026
pulisher
Mar 12, 2026

Is It Time To Revisit Axsome Therapeutics (AXSM) After Recent Share Price Weakness - simplywall.st

Mar 12, 2026
pulisher
Mar 12, 2026

Johnson Fistel, PLLP Investigates Claims on Behalf of - GlobeNewswire

Mar 12, 2026
pulisher
Mar 10, 2026

Axsome Therapeutics at The Citizens Life Sciences Conference: Strategic Growth Plans - Investing.com Canada

Mar 10, 2026
pulisher
Mar 10, 2026

AXSM: Major 2026 catalysts include Auvelity's PDUFA for Alzheimer's agitation and field force expansion - TradingView

Mar 10, 2026
pulisher
Mar 10, 2026

AXSM: April 2026 PDUFA for Auvelity in Alzheimer's agitation is a key near-term catalyst - TradingView

Mar 10, 2026
pulisher
Mar 10, 2026

A Look At Axsome Therapeutics (AXSM) Valuation After Priority Review And 2025 Revenue Growth - Yahoo Finance

Mar 10, 2026
pulisher
Mar 10, 2026

2 Under-the-Radar Stocks to Buy and Hold - The Globe and Mail

Mar 10, 2026
pulisher
Mar 10, 2026

Axsome Therapeutics Highlights Auvelity Sales Push, April 30 PDUFA, and Symbravo Launch Updates - MarketBeat

Mar 10, 2026
pulisher
Mar 10, 2026

Inceptionr LLC Invests $1.05 Million in Axsome Therapeutics, Inc. $AXSM - MarketBeat

Mar 10, 2026
pulisher
Mar 09, 2026

Axsome Therapeutics at Leerink Conference: Strategic Growth and Challenges By Investing.com - Investing.com Canada

Mar 09, 2026
pulisher
Mar 09, 2026

AXSM: Auvelity accelerates growth and pipeline advances with major expansions and new clinical programs - TradingView

Mar 09, 2026
pulisher
Mar 08, 2026

Axsome Therapeutics, Inc. $AXSM is Rhenman & Partners Asset Management AB's 8th Largest Position - MarketBeat

Mar 08, 2026
pulisher
Mar 06, 2026

(AXSM) Movement as an Input in Quant Signal Sets - Stock Traders Daily

Mar 06, 2026
pulisher
Mar 06, 2026

Axsome Therapeutics, Inc. $AXSM Shares Sold by Quantbot Technologies LP - MarketBeat

Mar 06, 2026
pulisher
Mar 05, 2026

Axsome Therapeutics touts AUVELITY $155M quarter, doubles salesforce ahead of April FDA decision - MarketBeat

Mar 05, 2026
pulisher
Mar 05, 2026

Royce & Associates LP Raises Position in Axsome Therapeutics, Inc. $AXSM - MarketBeat

Mar 05, 2026
pulisher
Mar 05, 2026

Axsome Therapeutics, Inc. $AXSM Shares Sold by Intech Investment Management LLC - MarketBeat

Mar 05, 2026
pulisher
Mar 04, 2026

Assessing Axsome Therapeutics (AXSM) Valuation After Earnings Momentum And New Phase 3 Trial Launch - simplywall.st

Mar 04, 2026
pulisher
Mar 04, 2026

AXSM Earnings History & Surprises | EPS & Revenue Results | AXSOME THERAPEUTICS INC (NASDAQ:AXSM) - ChartMill

Mar 04, 2026
pulisher
Mar 04, 2026

Axsome Therapeutics, Inc. $AXSM Position Boosted by TD Asset Management Inc - MarketBeat

Mar 04, 2026
pulisher
Mar 03, 2026

Should Axsome’s Revenue Jump and SUNOSI IP Win Require Action From Axsome Therapeutics (AXSM) Investors? - simplywall.st

Mar 03, 2026
pulisher
Mar 02, 2026

AXSM: Robust late-stage pipeline and sales force expansion drive growth across CNS and pain markets - TradingView

Mar 02, 2026
pulisher
Mar 02, 2026

AXSM: AUVELITY and pipeline assets drive growth, with key FDA decisions and launches ahead - TradingView

Mar 02, 2026
pulisher
Mar 02, 2026

Axsome Therapeutics (AXSM): Analyst Consensus Highlights 35% Potential Upside for This Biotech Innovator - DirectorsTalk Interviews

Mar 02, 2026
pulisher
Mar 02, 2026

Axsome Therapeutics Aktie: Wachstumskurs bestätigt - sharewise.com

Mar 02, 2026
pulisher
Mar 01, 2026

DNB Asset Management AS Increases Stock Position in Axsome Therapeutics, Inc. $AXSM - MarketBeat

Mar 01, 2026
pulisher
Mar 01, 2026

Axsome Therapeutics, Inc. $AXSM Shares Bought by JPMorgan Chase & Co. - MarketBeat

Mar 01, 2026
pulisher
Feb 28, 2026

Axsome Therapeutics, Inc. (AXSM): A Bull Case Theory - Bitget

Feb 28, 2026
pulisher
Feb 28, 2026

Axsome Explores Solriamfetol In Phase 3 CLARITY Trial For MDD Subset - Sahm

Feb 28, 2026
pulisher
Feb 28, 2026

Citigroup Inc. Boosts Position in Axsome Therapeutics, Inc. $AXSM - MarketBeat

Feb 28, 2026
pulisher
Feb 27, 2026

Axsome Therapeutics (NASDAQ:AXSM) COO Sells $5,726,990.64 in Stock - MarketBeat

Feb 27, 2026
pulisher
Feb 27, 2026

Mark Coleman Sells 25,000 Shares of Axsome Therapeutics (NASDAQ:AXSM) Stock - MarketBeat

Feb 27, 2026
pulisher
Feb 27, 2026

Axsome (NASDAQ: AXSM) CEO awarded 54,623 RSUs vesting by 2030 - Stock Titan

Feb 27, 2026
pulisher
Feb 27, 2026

[Form 4] Axsome Therapeutics, Inc. Insider Trading Activity - Stock Titan

Feb 27, 2026
pulisher
Feb 27, 2026

Axsome Therapeutics (AXSM) director completes 25,000-share 10b5-1 sale - Stock Titan

Feb 27, 2026
pulisher
Feb 27, 2026

Axsome Therapeutics Executives Sell Shares Worth Over $9.7 Million - TradingView

Feb 27, 2026

Axsome Therapeutics Inc (AXSM) 재무 분석

매출

loading

순이익

loading

현금흐름

loading

주당 순 이익

loading
$99.29
price up icon 1.20%
$27.80
price up icon 0.00%
$52.37
price down icon 0.06%
$89.31
price down icon 0.77%
$144.00
price up icon 0.91%
biotechnology ONC
$282.72
price up icon 0.15%
자본화:     |  볼륨(24시간):